Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BioCardia Q2 2026 Earnings Call - Japan Shonin Submission Imminent as FDA Confirms Single-Trial Pathway
BioCardia delivered a pivotal regulatory update in Q2 2026, securing critical green lights for its CardiAMP cell therapy in both Japan and the U.S. The Pharmaceuticals and Medical Devices Agency (PMDA...
- PMDA in Japan issued a Consultation Record of Advice supporting BioCardia’s advancement to a Shonin pre-market regulatory submission for CardiAMP cell therapy.
- The FDA confirmed via Q-Sub meeting that the ongoing CardiAMP Heart Failure II trial is viewed as a sufficient confirmatory study for U.S. market clearance, removing the need for multiple trials.
- BioCardia is preparing for the Shonin submission in Japan next quarter, with an expected approval timeline of approximately 12 months post-submission.
- +7 more takeaways
Leslie's Pool Supplies Q3 2026 Earnings Call - Guidance Withdrawn Amid Traffic Slump and Debt Restructuring Talks
Leslie’s Pool Supplies reported a sharp deterioration in third-quarter fiscal 2026 results, with sales falling 8.4% year-over-year to $458.5 million as softer consumer demand and unfavorable weather c...
- Sales declined 8.4% year-over-year to $458.5 million, driven by a 6.2% drop in comparable sales due to reduced customer traffic and the loss of revenue from 80 recently closed underperforming stores.
- The company has withdrawn its full-year fiscal 2026 guidance for both sales and adjusted EBITDA, refusing to provide a new outlook due to the evolving macroeconomic environment and weaker-than-expected peak season performance.
- Adjusted EBITDA fell sharply from $81.6 million in the prior year to $55.7 million, reflecting the combined impact of lower sales volume and gross margin compression.
- +9 more takeaways
Dolphin Entertainment {Q2} {2026} Earnings Call - Management Forecasts Profitability Surge as Non-Recurring Costs Roll Off
Dolphin Entertainment reported a modest 2.5% year-over-year revenue increase to $14.4 million in Q2 2026, but the headline number masks a temporary dip in profitability driven by $720,000 in one-time ...
- Q2 2026 revenue reached $14.4 million, up 2.5% year-over-year, while the first half saw a 3.8% increase to $27.2 million.
- Adjusted EBITDA for the quarter was approximately $243,000, down from $628,000 in Q2 2025, primarily due to non-recurring expenses.
- Management disclosed $360,000 in one-time retention bonuses and roughly $360,000 in elevated legal fees, both expected to normalize in Q3.
- +7 more takeaways
Red Robin Gourmet Burgers Q2 2026 Earnings Call - Momentum Builds as Refranchising Boosts Balance Sheet
Red Robin delivered a solid second quarter, driven by its 'First Choice' strategy that balances value-driven traffic with operational discipline. Same-store sales grew 1.3%, with traffic flat but outp...
- Same-store sales increased 1.3%, with traffic effectively flat but outperforming the industry by 40 basis points, marking the best traffic performance since Q1 2023.
- The 'Big Yummm Burger Deal' is successfully driving traffic and trials, with the company noting it mixes at healthy levels and resonates with value-seeking guests.
- Restaurant-level operating margin rose 20 basis points year-over-year to 14.7%, the highest second-quarter margin in four years, driven by labor efficiencies and cost discipline.
- +9 more takeaways
Longeveron Q2 2026 Earnings Call - ELPIS II Data Readout Imminent Amid Cash Crunch and Partnership Push
Longeveron is standing on the precipice of a binary outcome as it prepares to release top-line data from its Phase IIb ELPIS II trial for laromestrocel in hypoplastic left heart syndrome (HLHS) in mid...
- ELPIS II Top-Line Data: The primary catalyst for the stock is the top-line data readout from the Phase IIb ELPIS II trial in HLHS, expected in mid-September. Management has aligned the Statistical Analysis Plan (SAP) with the FDA, with database lock planned for August 31.
- Cash Runway Tightens: As of June 30, 2026, Longeveron held $10.1 million in cash and cash equivalents. Management warned that this capital is sufficient only to fund operations and capital expenditures through the fourth quarter of 2026, creating urgent pressure to secure partnerships or additional capital.
- Revenue Decline: Revenues for Q2 2026 were $0.3 million, a 10% decrease from the prior year period, driven primarily by the absence of contract manufacturing revenue. The company remains pre-commercial with no product sales.
- +7 more takeaways
Talphera Q2 2026 Earnings Call - Nafamostat Enrollment Hits 75% Amid Expanded Market Opportunity
Talphera is accelerating toward its commercialization goals with the NEPHRO-CRRT trial reaching 75% enrollment, positioning the company for a top-line data readout later this year and a potential NDA ...
- The NEPHRO-CRRT registrational trial has reached 75% enrollment with all final clinical sites activated and nephrologists serving as principal investigators, putting the company on track to complete enrollment later this year.
- Top-line data from the NEPHRO-CRRT study is expected approximately four to five weeks after full enrollment completion, followed by a PMA submission in the first half of 2027.
- Updated market research raises the estimated annual CRRT procedures in the U.S. to 200,000 by 2027, a 21% increase from the previous estimate of 165,000, indicating a larger total addressable market.
- +7 more takeaways
SKYX Platforms Q2 2026 Earnings Call - Record Revenue Growth and European Hotel Expansion
SKYX Platforms delivered a robust second quarter in 2026, posting record revenue of $25.3 million, a 14% sequential increase and the tenth consecutive quarter of year-over-year growth. This performanc...
- SKYX reported record Q2 2026 revenue of $25.3 million, up 14% from Q1 2026 and 10% year-over-year, marking ten consecutive quarters of YoY growth.
- Cash and cash equivalents rose significantly to $27.7 million as of June 30, 2026, up from $10.1 million at year-end 2025, providing ample runway to achieve cash flow positivity by year-end.
- The company secured major European hospitality contracts, including technology deployments for the Durham Marriott City Center, Group OTT’s brand standards, the Grand Hotel du Parc in France, and The Mozart Prague (Accor Hospitality).
- +7 more takeaways
Nortech Systems Incorporated Q2 2026 Earnings Call - Backlog Surges 25% as Medical Device Sales Drive Growth
Nortech Systems delivered a resilient second quarter, with net sales rising 9.3% to $33.5 million, fueled by a 36% surge in medical device revenue. While aerospace and defense sales dipped due to post...
- Net sales increased 9.3% year-over-year to $33.5 million, outpacing the prior year’s $30.7 million.
- Medical device sales jumped 36% year-over-year, driven by higher demand from existing customers and new program ramp-ups.
- Total order backlog reached $93.8 million, up 19.8% from June 2025, with 90-day shipment backlog up 25.8%.
- +7 more takeaways
BioStem Technologies Q2 2026 Earnings Call - Hospital Revenue Surges as Gross Margin Expansion Looms
BioStem Technologies delivered a decisive pivot toward its hospital-centric strategy in Q2 2026, driving revenue to $7.9 million, a 30% sequential jump fueled by the full integration of the acquired B...
- Revenue reached $7.9 million in Q2 2026, up from $6.1 million in Q1, driven by a full quarter of contribution from the acquired hospital business.
- Hospital revenue specifically grew to $6.7 million from $5.4 million in the prior quarter, confirming the success of the channel pivot.
- Gross margin held steady at 61%, but management flagged near-term pressure due to higher-cost inventory purchased post-acquisition.
- +11 more takeaways
SideChannel Q3 2024 Earnings Call - Revenue Turns Positive, Gross Margins Surge, But Going Concern Risk Remains
SideChannel reported its first year-over-year revenue growth in five quarters, with Q3 revenue ticking up 1.2% to $1.8 million. The more significant story is the structural shift in the business: cybe...
- Q3 2024 marked the first quarter of year-over-year revenue growth in five quarters, with revenue rising 1.2% to $1.8 million.
- Gross margins expanded significantly by 790 basis points to 54.9%, driven by a favorable shift in revenue mix and improved delivery team utilization.
- For the first time, cybersecurity software and services constituted the majority of revenue at 51.6%, overtaking the vCISO segment which fell to 48.4%.
- +9 more takeaways